TheStreet
MicroStrategy retains place in key index despite delisting threats
📉
AI Sentiment
Negative
3/10
- Home
- INSM
INSM
Insmed Incorporated
as of 12-18-2025 10:58am EST
$166.07
$32.39
-16.32%
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Chart Type:
Time Range:
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 41.2B | IPO Year: | 2000 |
| Target Price: | $188.05 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $60.40 - $212.75 | Next Earning Date: | 10-30-2025 |
| Revenue: | $447,022,000 | Revenue Growth: | 30.34% |
| Revenue Growth (this year): | 43.1% | Revenue Growth (next year): | 128.25% |
AI-Powered INSM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 16 hours ago
AI Recommendation
hold
Model Accuracy: 68.46%
68.46%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Insmed Incorporated (INSM)
SHAROKY MELVIN MD
Sell
Director
INSM Dec 5, 2025
Avg Cost/Share
$205.01
Shares
20,000
Total Value
$4,100,200.00
Owned After
243,948
SEC Form 4
Lewis William
Sell
Chair and CEO
INSM Dec 4, 2025
Avg Cost/Share
$206.05
Shares
10,699
Total Value
$2,199,914.53
Owned After
307,872
Flammer Martina M.D.
Sell
Chief Medical Officer
INSM Dec 1, 2025
Avg Cost/Share
$206.91
Shares
8,895
Total Value
$1,841,100.65
Owned After
84,670
ANDERSON ELIZABETH M
Sell
Director
INSM Nov 24, 2025
Avg Cost/Share
$204.58
Shares
5,000
Total Value
$1,022,900.00
Owned After
58,729
SEC Form 4
ANDERSON ELIZABETH M
Sell
Director
INSM Nov 14, 2025
Avg Cost/Share
$195.87
Shares
10,000
Total Value
$1,958,700.00
Owned After
58,729
SEC Form 4
Schaeffer Orlov S Nicole
Sell
Chief People Strategy Officer
INSM Nov 12, 2025
Avg Cost/Share
$194.10
Shares
30,000
Total Value
$5,820,060.94
Owned After
36,625
Flammer Martina M.D.
Sell
Chief Medical Officer
INSM Nov 11, 2025
Avg Cost/Share
$189.78
Shares
31,226
Total Value
$5,922,794.88
Owned After
84,670
Smith Michael Alexander
Sell
Chief Legal Officer
INSM Nov 3, 2025
Avg Cost/Share
$184.42
Shares
27,130
Total Value
$4,985,910.59
Owned After
80,690
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| SHAROKY MELVIN MD | INSM | Director | Dec 5, 2025 | Sell | $205.01 | 20,000 | $4,100,200.00 | 243,948 | |
| Lewis William | INSM | Chair and CEO | Dec 4, 2025 | Sell | $206.05 | 10,699 | $2,199,914.53 | 307,872 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Dec 1, 2025 | Sell | $206.91 | 8,895 | $1,841,100.65 | 84,670 | |
| ANDERSON ELIZABETH M | INSM | Director | Nov 24, 2025 | Sell | $204.58 | 5,000 | $1,022,900.00 | 58,729 | |
| LEE LEO | INSM | Director | Nov 17, 2025 | Sell | $195.48 | 75,000 | $14,692,249.30 | 54,677 | |
| ANDERSON ELIZABETH M | INSM | Director | Nov 14, 2025 | Sell | $195.87 | 10,000 | $1,958,700.00 | 58,729 | |
| Schaeffer Orlov S Nicole | INSM | Chief People Strategy Officer | Nov 12, 2025 | Sell | $194.10 | 30,000 | $5,820,060.94 | 36,625 | |
| Flammer Martina M.D. | INSM | Chief Medical Officer | Nov 11, 2025 | Sell | $189.78 | 31,226 | $5,922,794.88 | 84,670 | |
| Smith Michael Alexander | INSM | Chief Legal Officer | Nov 3, 2025 | Sell | $184.42 | 27,130 | $4,985,910.59 | 80,690 |
Latest Insmed Incorporated News
INSM Breaking Stock News: Dive into INSM Ticker-Specific Updates for Smart Investing
Simply Wall St.
How Investors Are Reacting To Insmed (INSM) Joining The Nasdaq-100 Index
📈
AI Sentiment
Highly Positive
8/10
Investing.com
Western Digital stock rises after inclusion in Nasdaq-100 Index
📈
AI Sentiment
Highly Positive
8/10
GuruFocus.com
200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Insmed (INSM): Assessing Valuation After a Strong Year of Share Price Gains
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Is It Too Late to Consider Insmed After a 179% Surge and DCF Upside?
📊
AI Sentiment
Positive
7/10
Compare INSM vs Leading Stocks
See how INSM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INSM Insmed Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.